Electronic Raman scattering in Magnetite, Spin vs. Charge gap

We report Raman scattering data of single crystals of magnetite (Fe3O4) with Verwey transition temperatures (Tv) of 123 and 117K, respectively. Both single crystals reveal broad electronic background extending up to 900 wavenumbers (~110 meV). Redistribution of this background is observed when samples are cooled below Tv. In particular, spectra of the low temperature phase show diminished background below 300 wavenumbers followed by an enhancement of the electronic background between 300 and 400 wavenumbers. To enhance the effect of this background redistribution we divide the spectra just below the transition by the spectra just above the transition. A resultant broad peak-like feature is observed, centered at 370 wavenumbers (45 meV). The peak position of this feature does not scale with the transition temperature. We discuss two alternative assignments of this feature to a spin or charge gap in magnetite.Comment: 4 figures, 1 tabl

Corrosion and Passivation of Fe and FeN Films

The role of nitrogen in corrosion and passivation of thin Fe-N films was studied. Sputtered films with different levels of nitrogen were characterized for composition, conductivity, stress, and crystallinity. Corrosion and passivation of the films were evaluated by electrochemical measurements combined with in situ ellipsometry and ex situ x-ray photoelectron spectroscopy. The results indicate that in deaerated solutions the primary action of N is to reduce the catalytic activity of the surface for the hydrogen reaction and thereby reduce corrosion. In aerated solutions the corrosion rate increases with N content. Kinetics of the protective oxide formation as a function of potential, percent N, and the presence of borate buffer are discussed in detail. The work is relevant to the behavior of oxide-free Fe-N surfaces in contact with mild, nearly neutral electrolytes, such as could be used in fabrication of magnetic recording heads

Something Else Going On? Diagnostic Uncertainty in Children with Chronic Pain and Their Parents.

Diagnostic uncertainty, the perceived lack of an accurate explanation of the patient's health problem, remains relatively unstudied in children. This study examined the prevalence, familial concordance, and correlates of diagnostic uncertainty in children and their parents presenting to a multidisciplinary pain clinic in the United States. One hundred and twenty-six parents and 91 of their children (Mage = 13.93 years, range = 8-18 years) completed a brief three-item measure of diagnostic uncertainty, as well as measures of pain-related distress and functioning. Forty-eight percent of children and 37% of parents believed something else was going on with the child's pain that doctors had not found out about yet. Across the three items, 66%-77% of children and their parents agreed in their endorsement of diagnostic uncertainty. Parents who believed that something else was going on with their child's pain had children with higher avoidance of pain-related activities (F = 5.601, p = 0.020) and lower pain willingness (F = 4.782, p = 0.032). Neither parent nor child diagnostic uncertainty was significantly related to the child's pain-related functioning. Diagnostic uncertainty, particularly in parents, is relevant in the experience of pediatric chronic pain and warrants further investigation as both a risk factor and therapeutic target

Book Reviews

Die hartJou Harl en Lewe. Deur A. J. Brink. Bl. 248. Gemustreer. RI6,95. Pretoria: Femina. 1982.The physiology of digestionExperiments and Observations on the Gastric Juice and the Physiology of Digestion. By William Beaumonr. 1st ed. 1&33. Reprinted in facsimile for the Classics ofMedicine Library, Division of Gryphon Editions Ltd, Birmingham, Alabama, 1980.Bone in Clinical Orthopaedics: A Study in ComparativeOsteology. Ed. by G. Sumner-Smith. Pp. xvi + 435. Illustrated. R94,25. Philadelphia: W. B. Saunders. 1982.Tamoxifen in breast cancerThe Role of Tamoxifen in Breast Cancer. Ed. by S. Iacobelli, M. E. Lippman and G. R. Della Cuna. Pp. xii + 124. Illustrated. 523,12. New York: Raven Press. 1982.Under the Influence. A History ofNitrous Oxide and OxygenAnaesthesia. By W. D. A. Smith. Pp. xxviii + 188. Illustrated. R33,50. London: Macmillan. 1982.Clinical internal medicine in the agedClinical Internal Medicine in the Aged. By R. W. Schrier. Pp. vii + 324. Illustrated. R61,-. Philadelphia: W. B. Saunders. 1982.Genital Infection by Chlamydia Trachomatis (Current Topicsin Infection, No. 2). By J. D. Oriel and G. L. Ridgway. Pp. viii + 144. Illustrated. R32,20. London: Edward Arnold. 1982.Placental Function Tests. By T. Chard and A. Klopper. Pp. viii + 94. Illustrated. DM42,-. Berlin: Springer-Verlag. 1982.Therapeutic Heat and Cold. 3rd ed. Ed. by J. F. Lehmann. Pp. xiv + 641. Illustrated. Baltimore: Williams & Wilkins. 1982

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly. Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. Results: At day 35, heart size had reduced in the pimobendan group:median change in (Delta) LVIDDN -0.06 (IQR:-0.15 to + 0.02), P < 0.0001, and LA:Ao -0.08 (IQR:-0.23 to + 0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in Delta LVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in Delta LA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial

Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. Hypothesis/Objectives: Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. Animals: 360 client-owned dogs with MMVD with left atrial-to-aortic ratio >= 1.6, normalized left ventricular internal diameter in diastole >= 1.7, and vertebral heart sum >10.5. Methods: Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Results: Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). Conclusions and Clinical Importance: Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit

ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs

This report, issued by the ACVIM Specialty of Cardiology consensus panel, revises guidelines for the diagnosis and treatment of myxomatous mitral valve disease (MMVD, also known as endocardiosis and degenerative or chronic valvular heart disease) in dogs, originally published in 2009. Updates were made to diagnostic, as well as medical, surgical, and dietary treatment recommendations. The strength of these recommendations was based on both the quantity and quality of available evidence supporting diagnostic and therapeutic decisions. Management of MMVD before the onset of clinical signs of heart failure has changed substantially compared with the 2009 guidelines, and new strategies to diagnose and treat advanced heart failure and pulmonary hypertension are reviewed

Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer - a multi-centre North London experience

© The Author(s) 2020. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Background Four months after the first known case of the 2019 novel coronavirus disease (COVID-19), on the 11th March 2020, the WHO declared the outbreak a pandemic and acknowledged the potential to overwhelm national healthcare systems. The high prevalence and associated healthcare, social and economic challenges of COVID-19 suggest this pandemic is likely to have a major impact on cancer management, and has been shown to potentially have worse outcomes in this cohort of vulnerable patients (1). This study aims to compare the outcomes of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed COVID-19 positive disease in patients with or without a history of cancer. Method: We retrospectively collected clinical, pathological and radiological characteristics and outcomes of COVID-19 RT-PCR positive cancer patients treated consecutively in four different North London hospitals (cohort A). Outcomes recorded included morbidity, mortality and length of hospital stay. All clinically relevant outcomes were then compared to consecutively admitted COVID-19 positive patients, without a history of cancer (cohort B), treated at the primary centre during the same time period (12th March- 7th April 2020). Results: A total of 52 electronic patient records during the study time period were reviewed. Cohort A (median age 76 years, 56% males) and cohort B (median age 58 years, 62% male) comprised of 26 patients each. With the exclusion of cancer, both had a median of 2 comorbidities. Within cohort A, the most frequent underlying cancer was colorectal (5/26) and prostate cancer (5/26), and 77% of patients in Cohort A had received previous anti-cancer therapy. The most common presenting symptoms were cough and pyrexia in both cohorts. Frequent laboratory findings included lymphopenia, anaemia and elevated CRP in both cohorts, whilst hypokalaemia, hypoalbuminaemia and hypoproteinaemia was predominantly seen amongst patients with cancer. Median duration of admission was 7 days in both cohorts. The mortality rate was the same in both cohorts (23%), with median age of mortality of 80 years. Of cancer patients who died, all were advanced stage, had been treated with palliative intent and had received anti-cancer therapy within 13 days of admission. Conclusion: Old age, late stage of cancer diagnosis and multiple co-morbidities adversely influence the outcome of patients with COVID-19 positive patients. Whilst extra caution is warranted in the administration of anti-cancer therapies pertaining to the risk of immune-suppression, this data does not demonstrate a higher risk to cancer patients compared to their non-cancer counterparts.Peer reviewedFinal Published versio